Human LILRB4/CD85k/ILT3 Protein

产品信息(Product Info)

Recombinant Human LILRB4/CD85k/ILT3 Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Gln22-His257.[Accession | AAH26309]

分子量大小(Molecular Weight)

The protein has a predicted MW of 28.6 kDa. Due to glycosylation, the protein migrates to 38-42 kDa based on Tris-Bis PAGE result.


Less than 1EU per μg by the LAL method.


> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC


Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.


Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.


-20 to -80°C for 12 months as supplied from date of receipt.
-20 to -80°C for 3-6 months in unopened state after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please avoid freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Human LILRB4 on Tris-Bis PAGE under reduced conditions. The purity is greater than 95%.


The purity of Human LILRB4 is greater than 95% as determined by SEC-HPLC.


Immobilized Human LILRB4, His Tag at 0.5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-LILRB4 Antibody, hFc Tag with the EC50 of 7.8ng/ml determined by ELISA.

SPR Data

Human APOE4, hFc Tag captured on CM5 Chip via Protein A can bind Human LILRB4, His Tag with an affinity constant of 11.87 nM as determined in SPR assay (Biacore T200).


LILRB4,also known as CD85k and LIR-5, ILT-3,  is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT-3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.


HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K


(1)Samuel J , Heyu C , Mi D , et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML[J]. Molecular Therapy, 2018:S1525001618303721-.